Robert Davis, CEO of US pharmaceutical company Merck & Company (MSD), said on the 28th local time that it is expected to prepare 10 million doses of COVID-19 treatment pills by the end of the year, subject to the approval of the health authorities.
In an interview with CNBC, CEO Davis said on the same day, “At the moment, we can secure 10 million doses before the end of the year.”
Earlier, Merck & Company, together with Ridgevac Biotherapeutics, developed ‘molnupiravir’, an oral antiviral drug for COVID-19, and applied for emergency use to the US Food and Drug Administration (FDA).
According to the clinical trial results, this treatment showed the effect of reducing the hospitalization rate and death rate for COVID-19 by half.
The FDA’s external advisory body will hold a meeting on the 30th of next month to decide whether to recommend emergency use approval for molnupiravir.
“With clinical studies and data, I can tell you that this is a safe drug,” Davis said in an interview.
[사진 출처 : 로이터=연합뉴스]